{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:10Z","timestamp":1792787830858,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yunnan Fundamental Research Kunming Medical University Projects","award":["202401AY070001-094"],"award-info":[{"award-number":["202401AY070001-094"]}],"id":[{"id":"https:\/\/ror.org\/038c3w259","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16355-x","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:58:22Z","timestamp":1783090702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plexin A2 regulated the metastasis in breast cancer through MCM7"],"prefix":"10.1186","volume":"26","author":[{"given":"Chenghong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"4","key":"16355_CR1","first-page":"496","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocr Resist Breast Cancer Cancer Cell. 2020;37(4):496\u2013513.","journal-title":"Overcoming Endocr Resist Breast Cancer Cancer Cell"},{"issue":"1","key":"16355_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"16355_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"16355_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"C Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C, Lippi G. Current Cancer Epidemiology. J Epidemiol Glob Health. 2019;9(4):217\u201322.","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"16355_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s12885-021-08318-1","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers. BMC Cancer. 2021;21(1):644.","journal-title":"BMC Cancer"},{"issue":"Suppl 2","key":"16355_CR6","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26\u201335.","journal-title":"Breast"},{"issue":"3","key":"16355_CR7","first-page":"288","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: Rev Jama. 2019;321(3):288\u2013300.","journal-title":"Breast Cancer Treatment: Rev Jama"},{"issue":"6","key":"16355_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, et al. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619\u201326.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"16355_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/cco-20-123","volume":"9","author":"M Takada","year":"2020","unstructured":"Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9(3):32.","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"16355_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9(2):176\u201398.","journal-title":"Cancer Discov"},{"issue":"4","key":"16355_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2020;18(4):479\u201389.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1473","key":"16355_CR12","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1098\/rstb.2006.1892","volume":"361","author":"RJ Pasterkamp","year":"2006","unstructured":"Pasterkamp RJ, Verhaagen J. Semaphorins in axon regeneration: developmental guidance molecules gone wrong? Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1499\u2013511.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"16355_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fimmu.2020.00346","volume":"11","author":"V Iragavarapu-Charyulu","year":"2020","unstructured":"Iragavarapu-Charyulu V, Wojcikiewicz E, Urdaneta A. Semaphorins in Angiogenesis and Autoimmune Diseases: Therapeutic Targets? Front Immunol. 2020;11:346.","journal-title":"Front Immunol"},{"key":"16355_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2018.01.040","volume":"418","author":"J Wang","year":"2018","unstructured":"Wang J, et al. NRP-2 in tumor lymphangiogenesis and lymphatic metastasis. Cancer Lett. 2018;418:176\u201384.","journal-title":"Cancer Lett"},{"issue":"1","key":"16355_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrrheum.2017.201","volume":"14","author":"M Nishide","year":"2018","unstructured":"Nishide M, Kumanogoh A. The role of semaphorins in immune responses and autoimmune rheumatic diseases. Nat Rev Rheumatol. 2018;14(1):19\u201331.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"16355_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbcan.2019.05.004","volume":"1872","author":"S Vivekanadhan","year":"2019","unstructured":"Vivekanadhan S, Mukhopadhyay D. Divergent roles of Plexin D1 in cancer. Biochim Biophys Acta Rev Cancer. 2019;1872(1):103\u201310.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"16355_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lfs.2019.01.060","volume":"222","author":"J Zhuang","year":"2019","unstructured":"Zhuang J, et al. Sema6A-plexin-A2 axis stimulates RANKL-induced osteoclastogenesis through PLC\u03b3-mediated NFATc1 activation. Life Sci. 2019;222:29\u201335.","journal-title":"Life Sci"},{"issue":"1","key":"16355_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41419-023-05554-0","volume":"14","author":"S Toledano","year":"2023","unstructured":"Toledano S, et al. Plexin-A2 enables the proliferation and the development of tumors from glioblastoma derived cells. Cell Death Dis. 2023;14(1):41.","journal-title":"Cell Death Dis"},{"key":"16355_CR19","doi-asserted-by":"publisher","first-page":"732501","DOI":"10.3389\/fonc.2021.732501","volume":"11","author":"A Tyumentseva","year":"2021","unstructured":"Tyumentseva A, et al. Transcriptomic Profiling Revealed Plexin A2 Downregulation With Migration and Invasion Alteration in Dacarbazine-Treated Primary Melanoma Cells. Front Oncol. 2021;11:732501.","journal-title":"Front Oncol"},{"issue":"3","key":"16355_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-021-06286-5","volume":"189","author":"CL Wang","year":"2021","unstructured":"Wang CL, et al. Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein. Breast Cancer Res Treat. 2021;189(3):607\u201319.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"16355_CR21","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00216-015-9228-7","volume":"408","author":"R Chen","year":"2016","unstructured":"Chen R, et al. Identification of a novel mitochondrial interacting protein of C1QBP using subcellular fractionation coupled with CoIP-MS. Anal Bioanal Chem. 2016;408(6):1557\u201364.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"16355_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12967-022-03416-5","volume":"20","author":"Z Pu","year":"2022","unstructured":"Pu Z, et al. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K\/AKT\/mTOR pathway. J Transl Med. 2022;20(1):212.","journal-title":"J Transl Med"},{"issue":"7","key":"16355_CR23","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1111\/jcmm.16436","volume":"25","author":"X Li","year":"2021","unstructured":"Li X, et al. PRMT5 promotes colorectal cancer growth by interaction with MCM7. J Cell Mol Med. 2021;25(7):3537\u201347.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"16355_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ajpath.2012.11.020","volume":"182","author":"XY Zhang","year":"2013","unstructured":"Zhang XY, et al. Interaction of MCM7 and RACK1 for activation of MCM7 and cell growth. Am J Pathol. 2013;182(3):796\u2013805.","journal-title":"Am J Pathol"},{"issue":"3","key":"16355_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13304-017-0424-1","volume":"69","author":"Z Anastasiadi","year":"2017","unstructured":"Anastasiadi Z, et al. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313\u20137.","journal-title":"Updates Surg"},{"issue":"21","key":"16355_CR26","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1158\/0008-5472.CAN-20-1030","volume":"80","author":"P Bhat-Nakshatri","year":"2020","unstructured":"Bhat-Nakshatri P, et al. Breast Cancer Cell Detection and Characterization from Breast Milk-Derived Cells. Cancer Res. 2020;80(21):4828\u201339.","journal-title":"Cancer Res"},{"issue":"2","key":"16355_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2021.12.023","volume":"185","author":"T Risom","year":"2022","unstructured":"Risom T, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. 2022;185(2):299\u2013e31018.","journal-title":"Cell"},{"issue":"5","key":"16355_CR28","first-page":"M535","volume":"86","author":"O Peart","year":"2015","unstructured":"Peart O. Breast intervention and breast cancer treatment options. Radiol Technol. 2015;86(5):M535\u201358. quiz 559\u2009\u2013\u200962.","journal-title":"Radiol Technol"},{"issue":"11","key":"16355_CR29","first-page":"1339","volume":"81","author":"KL Maughan","year":"2010","unstructured":"Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician. 2010;81(11):1339\u201346.","journal-title":"Am Fam Physician"},{"issue":"2","key":"16355_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10549-018-4761-7","volume":"170","author":"DA Hill","year":"2018","unstructured":"Hill DA, et al. Breast cancer survival, survival disparities, and guideline-based treatment. Breast Cancer Res Treat. 2018;170(2):405\u201314.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"16355_CR31","first-page":"311","volume":"9","author":"OJ Scully","year":"2012","unstructured":"Scully OJ, et al. Breast cancer metastasis Cancer Genomics Proteom. 2012;9(5):311\u201320.","journal-title":"Breast cancer metastasis Cancer Genomics Proteom"},{"key":"16355_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-981-32-9620-6_9","volume":"1187","author":"MY Kim","year":"2021","unstructured":"Kim MY. Breast Cancer Metastasis Adv Exp Med Biol. 2021;1187:183\u2013204.","journal-title":"Breast Cancer Metastasis Adv Exp Med Biol"},{"issue":"8","key":"16355_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Peterse JL. van \u2018t Veer. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591\u2013602.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"16355_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607\u201317.","journal-title":"Cancer Immunol Immunother"},{"key":"16355_CR35","doi-asserted-by":"publisher","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, et al. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683.","journal-title":"Pharmacol Res"},{"key":"16355_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12967-015-0425-0","volume":"13","author":"R Ma","year":"2015","unstructured":"Ma R, et al. Mechanisms involved in breast cancer liver metastasis. J Transl Med. 2015;13:64.","journal-title":"J Transl Med"},{"key":"16355_CR37","doi-asserted-by":"crossref","unstructured":"Medeiros B, Allan AL. Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. Int J Mol Sci. 2019;20(9):2272.","DOI":"10.3390\/ijms20092272"},{"issue":"149","key":"16355_CR38","first-page":"211","volume":"27","author":"M Yang","year":"2019","unstructured":"Yang M, Liu C, Yu X. Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discov Med. 2019;27(149):211\u201320.","journal-title":"Discov Med"},{"issue":"3","key":"16355_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10555-020-09881-y","volume":"39","author":"M Hosonaga","year":"2020","unstructured":"Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020;39(3):711\u201320.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"16355_CR40","first-page":"290","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290\u2013303.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"16355_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s13046-019-1359-9","volume":"38","author":"P Song","year":"2019","unstructured":"Song P, et al. Estrogen receptor \u03b2 inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. J Exp Clin Cancer Res. 2019;38(1):354.","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"16355_CR42","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","volume":"56","author":"F L\u00fc\u00f6nd","year":"2021","unstructured":"L\u00fc\u00f6nd F, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021;56(23):3203\u2013e322111.","journal-title":"Dev Cell"},{"key":"16355_CR43","doi-asserted-by":"crossref","unstructured":"Park M, et al. Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2022;23(12):6806.","DOI":"10.3390\/ijms23126806"},{"issue":"6","key":"16355_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.sbi.2004.10.010","volume":"14","author":"E Gherardi","year":"2004","unstructured":"Gherardi E, et al. The sema domain. Curr Opin Struct Biol. 2004;14(6):669\u201378.","journal-title":"Curr Opin Struct Biol"},{"key":"16355_CR45","doi-asserted-by":"crossref","unstructured":"Altintas DM, et al. The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor. Int J Mol Sci. 2022;23(20):12427.","DOI":"10.3390\/ijms232012427"},{"key":"16355_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1476-4598-9-307","volume":"9","author":"Q Ma","year":"2010","unstructured":"Ma Q, et al. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase. Mol Cancer. 2010;9:307.","journal-title":"Mol Cancer"},{"issue":"13","key":"16355_CR47","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2016-07-729400","volume":"129","author":"G Zhu","year":"2017","unstructured":"Zhu G, et al. The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy. Blood. 2017;129(13):1840\u201354.","journal-title":"Blood"},{"issue":"7","key":"16355_CR48","doi-asserted-by":"publisher","first-page":"e41912","DOI":"10.1371\/journal.pone.0041912","volume":"7","author":"KL Chao","year":"2012","unstructured":"Chao KL, et al. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. PLoS ONE. 2012;7(7):e41912.","journal-title":"PLoS ONE"},{"key":"16355_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2020.07.009","volume":"126","author":"X Huang","year":"2020","unstructured":"Huang X, et al. Identification of a dorsal transcription factor (MnDorsal) from Macrobrachium nipponense and its role in innate immunity. Mol Immunol. 2020;126:1\u20137.","journal-title":"Mol Immunol"},{"issue":"1","key":"16355_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/08923973.2021.1991372","volume":"44","author":"D Su","year":"2022","unstructured":"Su D. MCM7 affects the cisplatin resistance of liver cancer cells and the development of liver cancer by regulating the PI3K\/Akt signaling pathway. Immunopharmacol Immunotoxicol. 2022;44(1):17\u201327.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"16355_CR51","doi-asserted-by":"publisher","first-page":"41776","DOI":"10.1038\/srep41776","volume":"7","author":"Z Liang","year":"2017","unstructured":"Liang Z, et al. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Sci Rep. 2017;7:41776.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16355-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:37:07Z","timestamp":1790897827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16355-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16355"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16355-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent. The study was in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of The First Affiliated Hospital of Kunming Medical University (IRB No. 2024-L-262). Clinical trial number: not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1168"}}